Law ❯ Litigation ❯ Securities Litigation ❯ Class Action

Shareholder Rights

Cytokinetics Faces Wave of Investor Lawsuits as Lead Plaintiff Deadline Nears

Plaintiffs allege Cytokinetics overstated its aficamten approval timeline by submitting an NDA without a REMS after FDA safety discussions.

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case